This study aimed to investigate the antitumor activity of new series of 2-thiohydanotin derivatives ( and ) against two cancer cell lines. A new series of 2-thioxoimidazolidine derivatives () were synthesized and investigated for its structure through spectral analysis and also tested against (HepG-2) and (HCT-116) cell line. Among the synthesized compounds, compound halted liver cancer cells at the G0/G1 phase and triggered apoptosis of liver cancer. Contrarily, compound caused colon cancer cells to be arrested at the S phase and trigger apoptosis. Also, they had a good inhibitory effect on (Nrf2). Both compounds had attractive lead molecules for the creation of colon and liver cancer medications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11352705PMC
http://dx.doi.org/10.1080/17568919.2024.2350925DOI Listing

Publication Analysis

Top Keywords

liver cancer
12
cancer cells
8
cancer
5
cytotoxicity screening
4
screening 3-substituted-4-oxo-imidazolidin-2-1h-thione
4
3-substituted-4-oxo-imidazolidin-2-1h-thione derivatives
4
derivatives anticancer
4
anticancer drug
4
drug study
4
study aimed
4

Similar Publications

Background: Early identification of the risk of early cancer-related death (within one year, ECRD) due to recurrence after liver resection for hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C is important for surgeons to make clinical decisions. Our study aimed to establish a nomogram to predict the ECRD due to recurrence for HCC patients with BCLC stage B/C.

Methods: A total of 672 HCC patients with BCLC stages B/C from four medical centers between January 2012 and December 2018 were included in our study.

View Article and Find Full Text PDF

Background: Minimal access liver surgery (MALS) is considered superior to open liver resection (OLR) in reducing the perioperative risk in patients affected by hepatocellular carcinoma (HCC). No national-level comparisons exist based on procedure complexity. This study aims to compare postoperative complications, postoperative ascites (POA), and major complications (MC) between MALS and OLR.

View Article and Find Full Text PDF

Background: Anti-programmed cell death protein 1 (anti-PD-1) antibodies have achieved revolutionary success in cancer therapy. However, the impact of anti-PD-1 therapy on host humoral immunity in humans during cancer immunotherapy requires further investigation.

Methods: We evaluated immunoglobulin titers by ELISA and screened the immune landscape of immune cells from 25 healthy donors and 50 cases including 25 new-onset hepatocellular carcinoma (HCC) patients prior to systemic treatment and 25 HCC patients undergoing anti-PD-1 therapy by multicolor flow cytometry.

View Article and Find Full Text PDF

MAF1 inhibits hepatocarcinogenesis by fostering an immunostimulatory tumor microenvironment.

J Immunother Cancer

January 2025

State Key Laboratory of Oncology in South China, and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

Background: The biological significance of MAF1, a tumor suppressor, in carcinogenesis and immune response of hepatocellular carcinoma (HCC) remains unreported. Understanding the underlying mechanisms by which MAF1 enhances anti-tumor immunity in HCC is crucial for developing novel immunotherapy strategies and enhancing clinical responses to treatment for patients with HCC.

Methods: Mice were subjected to hydrodynamic tail vein injections of transposon vectors to overexpress AKT/NRas, or c-Myc, with or without wild-type (WT) or mutant-activated (-4A) MAF1, or short-hairpin MAF1 (shMAF1).

View Article and Find Full Text PDF

J. Ding, "Effect of Retrieval Bags in Preventing Surgical Site Wound Infection During Elective Laparoscopic Cholecystectomy in Liver Cancer Patients: A Meta-Analysis," International Wound Journal 20, no. 10 (2023): 4031-4039, https://doi.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!